Illinois Municipal Retirement Fund lessened its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 233,632 shares of the company’s stock after selling 2,946 shares during the quarter. Johnson & Johnson comprises approximately 0.9% of Illinois Municipal Retirement Fund’s portfolio, making the stock its 7th largest position. Illinois Municipal Retirement Fund’s holdings in Johnson & Johnson were worth $41,271,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lincoln Capital Corp raised its position in Johnson & Johnson by 15.9% in the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after purchasing an additional 183 shares during the period. Ieq Capital LLC grew its stake in shares of Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after acquiring an additional 6,154 shares in the last quarter. RFG Advisory LLC grew its stake in shares of Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after acquiring an additional 594 shares in the last quarter. Willis Investment Counsel grew its stake in shares of Johnson & Johnson by 0.4% in the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after acquiring an additional 1,358 shares in the last quarter. Finally, Wambolt & Associates LLC grew its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after acquiring an additional 355 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Guggenheim began coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price for the company. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They set a “strong-buy” rating for the company. UBS Group began coverage on shares of Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price for the company. Finally, Morgan Stanley boosted their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.
Insider Activity
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $163.70 on Monday. The company has a 50-day simple moving average of $157.80 and a 200-day simple moving average of $167.05. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The stock has a market capitalization of $426.32 billion, a price-to-earnings ratio of 34.25, a PEG ratio of 2.78 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. During the same period in the prior year, the company earned $2.67 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.91%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 94.56%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.